Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor and the standard of care therapy for non-small cell lung cancer patients harboring EGFR-activating mutations. However, even for patients treated with osimertinib, resistance inevitably occurs leading to disease progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosibaty, Zeinab, Brustugun, Odd Terje, Zwicky Eide, Inger Johanne, Tsakonas, Georgios, Grundberg, Oscar, De Petris, Luigi, McGowan, Marc, Hydbring, Per, Ekman, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317954/
https://www.ncbi.nlm.nih.gov/pubmed/35884490
http://dx.doi.org/10.3390/cancers14143430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317954/
https://www.ncbi.nlm.nih.gov/pubmed/35884490
http://dx.doi.org/10.3390/cancers14143430

Ejemplares similares